GlassScriptPhysician profile
Priya Patel
NPI 1043698749
$13,076.11
in general payments reported to CMS, 2019-2025
23 companies · $4,158 in 2025
The $4,158 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $119 · 2021: $1,406 · 2022: $1,423 · 2023: $2,616 · 2024: $3,205 · 2025: $4,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,479 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,479.30 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $7,223.95 | 2020-2025 | Kxl System, Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Alcon Vision LLC | $1,319.15 | 2019-2025 | Clareon, Rocklatan, Precision 1 |
| Biotissue Holdings INC. | $946.71 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $486.37 | 2020-2023 | Cequa |
| Oyster Point Pharma, INC. | $420.00 | 2023-2025 | Tyrvaya, Ryzumvi |
| Amgen INC. | $386.76 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $250.72 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $224.58 | 2020-2024 | Veritas Vision System, Tecnis Iol, Tecnis Simplicity |
| Dompe US, INC. | $200.42 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $186.15 | 2023-2024 | Envista Mx60 Iol, Miebo |
| Rxsight INC | $176.64 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Horizon Therapeutics Plc | $168.83 | 2023 | Tepezza |
| Harrow Eye, LLC | $145.41 | 2025 | Vevye |
| Carl Zeiss Meditec USA, INC. | $127.98 | 2022 | |
| Eyepoint US, INC. | $127.79 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $121.63 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Apellis Pharmaceuticals, INC. | $119.02 | 2023 | Syfovre |
| Genentech USA, INC. | $114.59 | 2024 | Vabysmo |
| New World Medical,INC. | $102.87 | 2021 | |
| Abbvie INC. | $97.09 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $54.11 | 2022-2023 | |
| Nova Eye, INC. | $40.03 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $35.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.